| Type: | combo |
| Component1: | Dolutegravir |
| Class1: | Integrase strand transfer inhibitor |
| Component2: | Lamivudine |
| Class2: | Nucleoside reverse transcriptase inhibitor |
| Component3: | Tenofovir disoproxil |
| Class3: | Nucleoside reverse transcriptase inhibitor |
| Routes Of Administration: | By mouth |
| Atc Prefix: | J05 |
| Atc Suffix: | AR27 |
| Synonyms: | Tenofovir/lamivudine/dolutegravir (TLD) |
Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.[1] It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil.[1], it is listed by the World Health Organization (WHO) as the first line treatment for adults, with tenofovir/lamivudine/efavirenz as an alternative.[2] It is taken by mouth.[3]
Side effects may include trouble sleeping, weight gain, and rash.[2] [3] While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use.[2] Use remains recommended after the first trimester.[2] Use is not recommended in those with kidney problems.[3] The combination is a type of antiretroviral therapy.[2]
It is on the World Health Organization's List of Essential Medicines.[4] In some countries it is available as a generic medication.[5] It is tentatively approved in the United States as of 2019, full approval is pending expiration of the US patents on dolutegravir (Tivicay) and tenofovir disoproxil (Viread).[6] [7]
As of 2019, it is listed by the World Health Organization (WHO) as the first-line treatment for adults with HIV/AIDS, with tenofovir/lamivudine/efavirenz as an alternative.[2] It may be used in people with both HIV and tuberculosis, however if the person is on rifampicin a larger dose of dolutegravir is needed.[2]
Side effects may include trouble sleeping and weight gain.[2] While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use.[2] Use remains recommended after the first trimester.[2] It should not be used with dofetilide.[3]
In the developing world it costs about per year.[8] It is considered more cost effective than tenofovir/lamivudine/efavirenz as of 2019.[2]